Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier

Add time:07/29/2019    Source:sciencedirect.com

PurposeThe objective of the current study was to determine the ability of some antiemetic compounds to cross the blood–brain barrier (BBB) and thereby to determine possible side effects of compounds for the central nervous system (CNS).

We also recommend Trading Suppliers and Manufacturers of Metopimazine Acid (cas 18182-00-8). Pls Click Website Link as below: cas 18182-00-8 suppliers

Prev:Stability indicating HPTLC method for determination of Metopimazine in pharmaceutical formulation and human plasma
Next:Effect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine)